Biofarm Bucure (BIO) - Net Assets
Based on the latest financial reports, Biofarm Bucure (BIO) has net assets worth RON548.53 Million RON (≈ $125.95 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RON634.39 Million ≈ $145.67 Million USD) and total liabilities (RON85.86 Million ≈ $19.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Biofarm Bucure to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RON548.53 Million |
| % of Total Assets | 86.47% |
| Annual Growth Rate | 13.45% |
| 5-Year Change | 64.83% |
| 10-Year Change | N/A |
| Growth Volatility | 1.56 |
Biofarm Bucure - Net Assets Trend (2019–2025)
This chart illustrates how Biofarm Bucure's net assets have evolved over time, based on quarterly financial data. Also explore BIO total asset value for the complete picture of this company's asset base.
Annual Net Assets for Biofarm Bucure (2019–2025)
The table below shows the annual net assets of Biofarm Bucure from 2019 to 2025. For live valuation and market cap data, see BIO market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | RON548.53 Million ≈ $125.95 Million |
+14.69% |
| 2024-09-30 | RON478.26 Million ≈ $109.82 Million |
+10.09% |
| 2023-09-30 | RON434.41 Million ≈ $99.75 Million |
+14.30% |
| 2022-09-30 | RON380.06 Million ≈ $87.27 Million |
+14.20% |
| 2021-09-30 | RON332.79 Million ≈ $76.41 Million |
+14.14% |
| 2020-09-30 | RON291.55 Million ≈ $66.94 Million |
+13.34% |
| 2019-09-30 | RON257.23 Million ≈ $59.06 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biofarm Bucure's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 656.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RON416.19 Million | 75.87% |
| Other Components | RON132.34 Million | 24.13% |
| Total Equity | RON548.53 Million | 100.00% |
Biofarm Bucure Competitors by Market Cap
The table below lists competitors of Biofarm Bucure ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Can2 Termik AS
IS:CANTE
|
$280.64 Million |
|
Hung Ching Development & Construction Co Ltd
TW:2527
|
$280.80 Million |
|
Lanzhou Huanghe Enterprise Co Ltd
SHE:000929
|
$280.80 Million |
|
Jindal Worldwide Limited
NSE:JINDWORLD
|
$280.83 Million |
|
Sappe Public Company Limited
BK:SAPPE
|
$280.54 Million |
|
Planigrupo LATAM S.A.B. de C.V
MX:PLANI
|
$280.54 Million |
|
Roman DBDR Acquisition Corp. II Unit
NASDAQ:DRDBU
|
$280.53 Million |
|
Adel Kalemcilik Ticaret ve Sanayi AS
IS:ADEL
|
$280.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biofarm Bucure's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 478,261,457 to 548,531,407, a change of 70,269,950 (14.7%).
- Net income of 100,816,587 contributed positively to equity growth.
- Other factors decreased equity by 30,546,637.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RON100.82 Million | +18.38% |
| Other Changes | RON-30.55 Million | -5.57% |
| Total Change | RON- | 14.69% |
Book Value vs Market Value Analysis
This analysis compares Biofarm Bucure's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.75x to 2.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | RON0.26 | RON1.24 | x |
| 2020-09-30 | RON0.30 | RON1.24 | x |
| 2021-09-30 | RON0.34 | RON1.24 | x |
| 2022-09-30 | RON0.39 | RON1.24 | x |
| 2023-09-30 | RON0.44 | RON1.24 | x |
| 2024-09-30 | RON0.49 | RON1.24 | x |
| 2025-09-30 | RON0.56 | RON1.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biofarm Bucure utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.38%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.57%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.16x
- Recent ROE (18.38%) is above the historical average (18.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 19.78% | 26.05% | 0.56x | 1.35x | RON25.16 Million |
| 2020 | 18.61% | 25.07% | 0.58x | 1.28x | RON25.11 Million |
| 2021 | 18.14% | 25.25% | 0.57x | 1.26x | RON27.08 Million |
| 2022 | 18.66% | 25.60% | 0.59x | 1.23x | RON32.91 Million |
| 2023 | 17.73% | 27.48% | 0.57x | 1.14x | RON33.57 Million |
| 2024 | 15.56% | 25.94% | 0.52x | 1.16x | RON26.57 Million |
| 2025 | 18.38% | 31.57% | 0.50x | 1.16x | RON45.96 Million |
Industry Comparison
This section compares Biofarm Bucure's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $817,036,815
- Average return on equity (ROE) among peers: 5.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biofarm Bucure (BIO) | RON548.53 Million | 19.78% | 0.16x | $280.56 Million |
| Antibiotice Ia (ATB) | $932.07 Million | 5.55% | 0.49x | $277.47 Million |
| ZENTIVA S.A. (SCD) | $702.00 Million | 6.23% | 0.45x | $723.41 Million |
About Biofarm Bucure
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescr… Read more